MDX-210 humanized Bispecific antibody targeting the HER-2 receptor: Began a Phase I/II trial in 42 patients at the NCI, to assess safety and toxicity, to determ

Medarex Inc. (MEDX), Annandale, N.J.

Read the full 58 word article

How to gain access

Continue reading with a
two-week free trial.